Report period | 2017 | 2018 | 2019 | 2020 | 2021 | Q3 22 |
---|---|---|---|---|---|---|
End date of the reporting period | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Capitalization, $ | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Capitalization, $ | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Enterprise Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Book Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Shareholders Book Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Current liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Noncurrent liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Total liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Debt | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Cash and cash equivalents | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Net debt | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Assets | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Total ordinary shares | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Ordinary share price | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
MOTS:US | Motus GI Holdings | Common share | - | US62014P1084 | $0.0004 |
Company name | Motus GI Holdings |
---|---|
Tags | #medtech |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services |
Business address | 1301 East Broward Boulevard 3rd Floor Suite 310 Fort Lauderdale, FL 33301 United States |
Mailing address | 1301 East Broward Boulevard 3rd Floor Suite 310 Fort Lauderdale, FL 33301 United States |
Website | ir.motusgi.com |
Information disclosure | www.sec.gov |